Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor

Summary

The insulin-like growth factor 1 receptor (IGF-1R) is known to promote survival and has also been implicated in the pathogenesis of several disease states, including cardiovascular disorders and cancer. Recently, we showed that binding of coagulation factor VIIa (FVIIa) to its receptor tissue factor (TF) protects cancer cells from TNF-related apoptosis inducing ligand (TRAIL)-induced apoptosis. Here we present evidence that this biological function of TF/FVIIa is dependent on the IGF-1R. IGF-1R inhibitors AG1024 and PPP as well as siRNA-mediated downregulation of IGF-1R, abolished the TF/FVIIa-mediated protection against TRAIL-induced apoptosis. Moreover, FVIIa rapidly induced a time- and concentration-dependent tyrosine phosphorylation of the IGF-1R in MDA-MB-231 breast cancer cells and in primary human monocytes, an event that was accompanied by IGF-1R chromatin binding and gene transcription. We hereby present novel evidence of a cross-talk between the coagulation and IGF-1R signalling systems, and propose that the IGF-1R is a key player in mediating TF/FVIIa-induced cell survival.

Keywords

Tissue factor - FVIIa - Apoptosis - IGF-1R - Cell signalling

• References

• 1 Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players.. J Mol Endocrinol 2011; 47: R1-10.
• 2 Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update.. Nat Rev Cancer 2012; 12: 159-169.
• 3 Scartozzi M, Bianconi M, Maccaroni E. et al. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.. Discov Med 2011; 11: 144-153.
• 4 Ellison GM, Waring CD, Vicinanza C. et al. Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms.. Heart 2012; 98: 5-10.
• 5 Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?. PharmacolRev 2010; 62: 199-236.
• 6 Favelyukis S, Till JH, Hubbard SR. et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.. Nat Struct Biol 2001; 8: 1058-1063.
• 7 Zhao D, Bakirtzi K, Zhan Y. et al. Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells.. J Biol Chem 2011; 286: 6092-6099.
• 8 Tu H, Xu C, Zhang W. et al. GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation.. J Neurosci 2010; 30: 749-759.
• 9 Aleksic T, Chitnis MM, Perestenko OV. et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.. Cancer Res 2010; 70: 6412-6419.
• 10 Sehat B, Tofigh A, Lin Y. et al. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor.. Sci Signal 2010; 3: ra10.
• 11 Warsito D, Sjostrom S, Andersson S. et al. Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF.. EMBO Rep 2012; 13: 244-250.
• 12 Zioncheck TF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism.. J Biol Chem 1992; 267: 3561-3564.
• 13 Mackman N, Morrissey JH, Fowler B. et al. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade.. Biochemistry 1989; 28: 1755-1762.
• 14 Rao LV, Pendurthi UR. Regulation of tissue factor coagulant activity on cell surfaces.. J Thromb Haemost 2012; 10: 2242-2253.
• 15 Siegbahn A, Johnell M, Nordin A. et al. TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC.. Arterioscler Thromb Vasc Biol 2008; 28: 135-141.
• 16 Wiiger MT, Prydz H. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells.. Thromb Haemost 2004; 92: 13-22.
• 17 Aberg M, Siegbahn A. Tissue Factor non-coagulant signalling - molecular mechanisms and biological consequences with focus on cell migration and apoptosis.. J Thromb Haemost 2013; 11: 817-825.
• 18 Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors.. Cancer 1992; 70: 1194-1201.
• 19 Shigemori C, Wada H, Matsumoto K. et al. Tissue factor expression and meta-static potential of colorectal cancer.. Thromb Haemost 1998; 80: 894-898.
• 20 Ueno T, Toi M, Koike M. et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.. Br J Cancer 2000; 83: 164-170.
• 21 Aberg M, Johnell M, Wickstrom M. et al. Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1).. Thromb Res 2011; 127: 141-148.
• 22 Soderberg O, Leuchowius KJ, Gullberg M. et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay.. Methods 2008; 45: 227-232.
• 23 Parrizas M, Gazit A, Levitzki A. et al. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins.. Endocrinology 1997; 138: 1427-1433.
• 24 Girnita A, Girnita L, del PF. et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.. Cancer Res 2004; 64: 236-242.
• 25 Siegbahn A, Johnell M, Sorensen BB. et al. Regulation of chemotaxis by the cytoplasmic domain of tissue factor.. Thromb Haemost 2005; 93: 27-34.
• 26 Peruzzi F, Prisco M, Morrione A. et al. Anti-apoptotic signaling of the insulinlike growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4.. J Biol Chem 2001; 276: 25990-25996.
• 27 Furlanetto RW, Dey BR, Lopaczynski W. et al. 14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor.. Biochem J 1997; 327: 765-771.
• 28 Neal CL, Yu D. 14-3-3zeta as a prognostic marker and therapeutic target for cancer.. Expert Opin Ther Targets 2010; 14: 1343-1354.
• 29 Sorensen BB, Rao LV, Tornehave D. et al. Antiapoptotic effect of coagulation factor VIIa.. Blood 2003; 102: 1708-1715.
• 30 Tsao BP, Fair DS, Curtiss LK. et al. Monocytes can be induced by lipopolysac-charide-triggered T lymphocytes to express functional factor VII/VIIa protease activity.. J Exp Med 1984; 159: 1042-1057.
• 31 Koizume S, Jin MS, Miyagi E. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.. Cancer Res 2006; 66: 9453-9460.
• 32 Borissoff JI, Heeneman S, Kilinc E. et al. Early atherosclerosis exhibits an enhanced procoagulant state.. Circulation 2010; 122: 821-830.
• 33 Abroun S, Ishikawa H, Tsuyama N. et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].. Blood 2004; 103: 2291-2298.
• 34 Awasthi V, Mandal SK, Papanna V. et al. Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae.. Arterioscler Thromb Vasc Biol 2007; 27: 1447-1455.
• 35 Huo H, Guo X, Hong S. et al. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction.. J Biol Chem 2003; 278: 11561-11569.
• 36 Muth H, Kreis I, Zimmermann R. et al. Differential gene expression in activated monocyte-derived macrophages following binding of factor VIIa to tissue factor.. Thromb Haemost 2005; 94: 1028-1034.
• 37 Kong W, McConalogue K, Khitin LM. et al. Luminal trypsin may regulate enter-ocytes through proteinase-activated receptor 2.. Proc Natl Acad Sci USA 1997; 94: 8884-8889.
• 38 Oikonomopoulou K, Hansen KK, Saifeddine M. et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs).. Biol Chem 2006; 387: 817-824.
• 39 Zabel BA, Allen SJ, Kulig P. et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades.. J Biol Chem 2005; 280: 34661-34666.
• 40 Neal CL, Xu J, Li P. et al. Overexpression of 14-3-3zeta in cancer cells activates PI3K via binding the p85 regulatory subunit.. Oncogene 2012; 31: 897-906.
• 41 Raper SE, Burwen SJ, Barker ME. et al. Translocation of epidermal growth factor to the hepatocyte nucleus during rat liver regeneration.. Gastroenterology 1987; 92: 1243-1250.
• 42 Bettermann K, Benesch M, Weis S. et al. SUMOylation in carcinogenesis.. Cancer Lett 2012; 316: 113-125.
• 43 Baake M, Doenecke D, Albig W. Characterisation of nuclear localisation signals of the four human core histones.. J Cell Biochem 2001; 81: 333-346.
• 44 Kaouass M, Beaulieu R, Balicki D. Histonefection: Novel and potent non-viral gene delivery.. J Control Release 2006; 113: 245-254.
• 45 Kouzarides T. Chromatin modifications and their function.. Cell 2007; 128: 693-705.
• 46 Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors.. Cell 1991; 65: 775-783.
• 47 Cheung P, Tanner KG, Cheung WL. et al. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation.. Mol Cell 2000; 5: 905-915.
• 48 Pan G, Ni J, Wei YF. et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL.. Science 1997; 277: 815-818.
• 49 Sato K, Niessner A, Kopecky SL. et al. TRAIL-expressing T cells induce apopto-sis of vascular smooth muscle cells in the atherosclerotic plaque.. J Exp Med 2006; 203: 239-250.
• 50 Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.. Curr Opin Cell Biol 2010; 22: 837-844.